Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

2012 • 7,361 citations

PD-1 blockade induces responses by inhibiting adaptive immune resistance

2014 • 5,750 citations

Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

2014 • 4,953 citations

PD-1 and Its Ligands in Tolerance and Immunity

2008 • 4,838 citations

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

2014 • 4,720 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 • 4,304 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 • 4,054 citations

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

2014 • 3,906 citations

Restoring function in exhausted CD8 T cells during chronic viral infection

2005 • 3,743 citations

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

2014 • 3,320 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 • 3,290 citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 • 3,044 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

2001 • 2,746 citations

CD28/B7 SYSTEM OF T CELL COSTIMULATION

1996 • 2,726 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 • 2,721 citations

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

2008 • 2,656 citations

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

1999 • 2,574 citations

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1999 • 2,380 citations

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

2014 • 2,254 citations

Ido expression by dendritic cells: tolerance and tryptophan catabolism

2004 • 2,235 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

2014 • 2,174 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

2014 • 2,071 citations

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

2015 • 1,997 citations

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

2012 • 1,988 citations

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

2008 • 1,887 citations

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

2005 • 1,854 citations

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

2010 • 1,779 citations

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

2001 • 1,761 citations

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

2005 • 1,746 citations

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

2009 • 1,604 citations

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

2007 • 1,603 citations

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

2011 • 1,570 citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 • 1,564 citations

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

2013 • 1,513 citations

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

2002 • 1,510 citations

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

2011 • 1,452 citations

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

2014 • 1,382 citations

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

1992 • 1,290 citations

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

2003 • 1,255 citations

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

2006 • 1,254 citations

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

2014 • 1,247 citations

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

2008 • 1,228 citations

Role of LAG-3 in Regulatory T Cells

2004 • 1,198 citations

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

2014 • 1,014 citations

The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells

2006 • 982 citations

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

2014 • 960 citations

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2012 • 953 citations

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

1994 • 950 citations

B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

2001 • 916 citations

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

2009 • 882 citations

B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

2001 • 850 citations

CD28 and CTLA‐4 coreceptor expression and signal transduction

2009 • 824 citations

LAG-3, a novel lymphocyte activation gene closely related to CD4.

1990 • 802 citations

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

2013 • 796 citations

Tumor-infiltrating NY-ESO-1–specific CD8 ⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

2010 • 792 citations

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

2013 • 758 citations

Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance

2003 • 674 citations

Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

2007 • 673 citations

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

2008 • 658 citations

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

2011 • 605 citations

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

2011 • 590 citations

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

2012 • 589 citations

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

2014 • 588 citations

Reversal of the TCR Stop Signal by CTLA-4

2006 • 584 citations

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

2013 • 524 citations

The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses

2003 • 516 citations

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

2007 • 509 citations

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

2014 • 501 citations

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

2014 • 431 citations

VISTA Is an Immune Checkpoint Molecule for Human T Cells

2014 • 427 citations

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

2015 • 426 citations

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

2009 • 375 citations

Recognition of Tumors by the Innate Immune System and Natural Killer Cells

2014 • 336 citations

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

2005 • 331 citations

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

2010 • 311 citations

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

2011 • 290 citations

Antagonists of PD-1 and PD-L1 in Cancer Treatment

2015 • 283 citations

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

2014 • 278 citations

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

2009 • 275 citations

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

1997 • 267 citations

Characterization of Mouse and Human B7-H3 Genes

2002 • 267 citations

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

2006 • 261 citations

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

2009 • 253 citations

Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma

2008 • 249 citations

Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF

2009 • 241 citations

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

2012 • 238 citations

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

2005 • 235 citations

Human prostate‐infiltrating CD8⁺ T lymphocytes are oligoclonal and PD‐1⁺

2009 • 227 citations

Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues

2014 • 209 citations

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

1994 • 188 citations

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells

2007 • 187 citations

B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28

1998 • 179 citations

B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells

2004 • 177 citations

Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

2012 • 174 citations

Fine tuning the immune response through B7‐H3 and B7‐H4

2009 • 165 citations

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

2014 • 159 citations

Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor

2003 • 157 citations

Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo

2014 • 153 citations

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

2005 • 152 citations

Mutational analysis of the interaction between CD4 and class II MHC: Class II antigens contact CD4 on a surface opposite the gp120-binding site

1991 • 146 citations

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors

2014 • 119 citations

Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells

1998 • 115 citations

Identification and characterization of a second CD4-like gene in teleost fish

2005 • 113 citations

Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases

2009 • 76 citations

Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding.

1993 • 74 citations

Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation

2014 • 72 citations

Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

2014 • 70 citations

Killer Immunoglobulin-like Receptors and Tumor Immunity

2014 • 60 citations

Densely Granulated Murine NK Cells Eradicate Large Solid Tumors

2012 • 51 citations

Current Perspectives on Immunotherapy

2014 • 33 citations